Fibroblast activation protein targeted compounds and use thereof
Radiopharmaceuticals targeting FAP, designed as Y-L-X conjugates, address the need for effective cancer and disease treatment by providing both imaging and therapeutic capabilities through targeted radionuclide delivery.
Patent Information
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- PERSPECTIVE THERAPEUTICS INC
- Filing Date
- 2024-12-12
- Publication Date
- 2026-06-18
AI Technical Summary
There is a need for alternative radiopharmaceuticals that can be safely and effectively used for the imaging and/or treating of cancer and other disease states, particularly targeting fibroblast activation protein (FAP) which is highly upregulated in various cancers and disease conditions.
Development of radiopharmaceuticals designed as Y-L-X conjugates, where Y is a radionuclide, L is a molecular linker, and X is a targeting molecular structure that binds to FAP, enabling imaging and therapeutic applications by utilizing radionuclides that emit gamma rays, beta particles, or alpha particles.
The developed radiopharmaceuticals provide effective imaging and treatment options for cancer and other diseases by targeting FAP, with specific examples demonstrating high binding affinity, metabolic stability, and tumor uptake.
Smart Images
Figure 1 Figure 2 
Figure 3